A Phase 2 interventional study of crenolanib and cytarabine in Newly Diagnosed AML With FLT3 Activating Mutations, sponsored by Arog Pharmaceuticals, Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-02.
Sponsored by Arog Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
This pilot study is designed to evaluate the safety and tolerability of oral crenolanib besylate given sequentially during standard induction and consolidation chemotherapy in patients with newly diagnosed AML with FLT3 activating mutations.
Arog Pharmaceuticals, Inc. is the lead sponsor of 17 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Negative pregnancy test (serum or urine) for women of (WOCBP)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be given cytarabine and daunorubicin during induction therapy plus crenolanib at 100 mg TID.
Drug: crenolanib · Drug: cytarabine · Drug: daunorubicin
Patients will be given cytarabine and idarubicin during induction therapy plus crenolanib at 100 mg TID.
Drug: crenolanib · Drug: cytarabine · Drug: idarubicin
Also known as: CP-868,596-26
Clinical Response to Crenolanib With Standard Induction Chemotherapy
To determine the response rate to crenolanib. Complete remission (CR) response criteria includes a post-baseline bone marrow (BM) biopsy or aspiration % blasts \<5%, the absence of Auer rods and extramedullary leukemia, absolute neutrophil count (ANC) \>1×10\^9/L and platelet count \>100×10\^9/L. Complete remission with incomplete blood count recovery (CRi) response includes all CR criteria met, except participant do not achieve either platelet or ANC recovery. Composite Complete CR response includes all subjects who achieve a CR and CRi. Partial Response (PR) response includes all CR criteria met except a decrease of ≥50% in % blasts in the BM aspirate or biopsy from baseline but within 5-25% or bone marrow blasts \<5% with persistent Auer rods. Refractory Disease response includes subjects who do not satisfy the criteria for CR, CRi or PR.
Time frame: 2 years
3-Year Overall Survival
Overall survival (OS) was measured from the date of the first dose of treatment to the date of death from any cause or to the last date that the patient was known to be alive. OS at 3-years is presented.
Time frame: 3 years
| Milestone | Participants Less Than or Equal to 60 Years of Age | Participants Greater Than 60 Years of Age |
|---|---|---|
| Started | 29 | 15 |
| Completed | 28 | 14 |
| Not completed | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
To determine the response rate to crenolanib. Complete remission (CR) response criteria includes a post-baseline bone marrow (BM) biopsy or aspiration % blasts \<5%, the absence of Auer rods and extramedullary leukemia, absolute neutrophil count (ANC) \>1×10\^9/L and platelet count \>100×10\^9/L. Complete remission with incomplete blood count recovery (CRi) response includes all CR criteria met, except participant do not achieve either platelet or ANC recovery. Composite Complete CR response includes all subjects who achieve a CR and CRi. Partial Response (PR) response includes all CR criteria met except a decrease of ≥50% in % blasts in the BM aspirate or biopsy from baseline but within 5-25% or bone marrow blasts \<5% with persistent Auer rods. Refractory Disease response includes subjects who do not satisfy the criteria for CR, CRi or PR.
| Participants | Participants Less Than or Equal to 60 Years of Age | Participants Greater Than 60 Years of Age | All Patients |
|---|---|---|---|
| Composite Complete Remission (CR + CRi) | 26 | 12 | 38 |
| Complete Remission (CR) | 22 | 12 | 34 |
| Complete Remission with incomplete count recovery (CRi) | 4 | 0 | 4 |
| Partial Remission (PR) | 0 | 1 | 1 |
| Refractory Disease | 3 | 1 | 4 |
| Not evaluable | 0 | 1 | 1 |
Overall survival (OS) was measured from the date of the first dose of treatment to the date of death from any cause or to the last date that the patient was known to be alive. OS at 3-years is presented.
| percentage of participants | Participants Less Than or Equal to 60 Years of Age | Participants Greater Than 60 Years of Age | All Patients |
|---|---|---|---|
| 3-Year Overall Survival | 71.4 (56.5 to 90.3) | 33.3 (16.3 to 68.2) | 58 (44.9 to 74.9) |
Collected over 3 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants Less Than or Equal to 60 Years of Age | 9/29 (31%) | 18/29 (62.1%) | 29/29 (100%) |
| Participants Greater Than 60 Years of Age | 10/15 (66.7%) | 12/15 (80%) | 15/15 (100%) |
| Event | Participants Less Than or Equal to 60 Years of Age | Participants Greater Than 60 Years of Age |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 7/29 | 4/15 |
| SepsisInfections and infestations | 4/29 | 3/15 |
| DehydrationMetabolism and nutrition disorders | 0/29 | 3/15 |
| DiarrhoeaGastrointestinal disorders | 1/29 | 2/15 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 2/29 | 2/15 |
| NauseaGastrointestinal disorders | 1/29 | 2/15 |
| PyrexiaGeneral disorders | 2/29 | 2/15 |
| PneumoniaInfections and infestations | 3/29 | 1/15 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/29 | 1/15 |
| Abdominal painGastrointestinal disorders | 2/29 | 0/15 |
| Event | Participants Less Than or Equal to 60 Years of Age | Participants Greater Than 60 Years of Age |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 18/29 | 12/15 |
| Febrile neutropeniaBlood and lymphatic system disorders | 13/29 | 11/15 |
| NauseaGastrointestinal disorders | 16/29 | 11/15 |
| Oedema peripheralGeneral disorders | 10/29 | 9/15 |
| Decreased appetiteMetabolism and nutrition disorders | 8/29 | 9/15 |
| PyrexiaGeneral disorders | 8/29 | 8/15 |
| VomitingGastrointestinal disorders | 15/29 | 7/15 |
| Periorbital oedemaEye disorders | 3/29 | 7/15 |
| FatigueGeneral disorders | 5/29 | 7/15 |
| Aspartate aminotransferase increasedInvestigations | 6/29 | 7/15 |
| Age, Continuous(years) | Participants Less Than or Equal to 60 Years of Age | Participants Greater Than 60 Years of Age | Total |
|---|---|---|---|
| Median | 51 (19 to 60) | 68 (61 to 75) | 57 (19 to 75) |
| Sex: Female, Male(Participants) | Participants Less Than or Equal to 60 Years of Age | Participants Greater Than 60 Years of Age | Total |
|---|---|---|---|
| Female | 15 | 7 | 22 |
| Male | 14 | 8 | 22 |
| Ethnicity (NIH/OMB)(Participants) | Participants Less Than or Equal to 60 Years of Age | Participants Greater Than 60 Years of Age | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 27 | 15 | 42 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Participants Less Than or Equal to 60 Years of Age | Participants Greater Than 60 Years of Age | Total |
|---|---|---|---|
| White | 22 | 12 | 34 |
| Asian | 3 | 2 | 5 |
| Black or African American | 1 | 1 | 2 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Other | 2 | 0 | 2 |
| FLT3 Mutations(Participants) | Participants Less Than or Equal to 60 Years of Age | Participants Greater Than 60 Years of Age | Total |
|---|---|---|---|
| ITD only | 23 | 10 | 33 |
| TKD only | 4 | 4 | 8 |
| ITD and TKD | 2 | 1 | 3 |
| Cytogenetics(Participants) | Participants Less Than or Equal to 60 Years of Age | Participants Greater Than 60 Years of Age | Total |
|---|---|---|---|
| Normal | 21 | 9 | 30 |
| Abnormal, not complex | 6 | 5 | 11 |
| Complex | 2 | 0 | 2 |
| Not Available | 0 | 1 | 1 |
| AML with Antecedent Hematological Disorders(Participants) | Participants Less Than or Equal to 60 Years of Age | Participants Greater Than 60 Years of Age | Total |
|---|---|---|---|
| No | 28 | 12 | 40 |
| Yes | 1 | 3 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Jan 2015, a primary completion of Dec 2019 and a completion of Dec 2019. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2024, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arog Pharmaceuticals, Inc.